OrbitoAsia Diagnostics


Combined Screening + NT – High risk screen (>1:250) was followed by NIPT and in case of a high risk in NIPT, would be followed by QFPCR and KT.


We are proud to introduce to you the Microarray test in this package. Combined Screening + NT – High risk screen (>1:250) was followed by NIPT and in case of a high risk in NIPT, would be followed by QFPCR and Microarray (60K).

What is Microarray ?

Chromosomal Microarray (CMA) is an array-based molecular cytogenetic technique that can overcome some limitations of a karyotype, and is particularly useful for its ability to detect submicroscopic gains and losses on every chromosome. This technique compares the genomic content (DNA) of a patient (target) with that of a normal control individual (or indi- viduals) and detects gains and losses (duplications and deletions) ranging in size from very large, including aneuploidy of entire chromosomes, to very small loss or gain (typically as small as about 200,000 base pairs or 0.2 Mb).

CMA in Prenatal Settings

The American Congress of Obstetricians and Gynecologists (ACOG) and the Society for Maternal- Fetal Medicine recommend CMA as a replacement for the fetal karyotype in patients with a pregnancy demonstrating one or more major structural abnormalities on ultrasound when undergoing invasive prenatal diagnosis

Feature Test

Chromosomal Microarray optima (315K), Prenatal, Amniotic Fluid/ Chorionic Villus Sampling
Chromosomal Microarray optima (315K), Autopsy,Products of Conception, or Stillbirth
Chromosomal Microarray Cytosure (750K), Prenatal, Amniotic Fluid/Chorionic Villus Sampling
Chromosomal Microarray Cytosure (750K), Autopsy, Products of Conception, or Stillbirth

CMA in Pediatric Settings

The American College of Medical Genetics (ACMG)1,American Academy of Pediatrics (AAP)2 and the American Academy of Neurology (AAN)3 all recommend chromosomal microarray testing for individuals with one or more of the following:

Feature Test

Chromosomal Microarray Cytosure (750K,ostnatal, Peripheral Blood
Chromosomal Microarray Optima (315K),Postnatal, Peripheral Blood

Orbitoasia Diagnostics - Chromosomal Microarray Offerings

Cytoscan 750K
Cytoscan Optima
Where to be Used?
CytoScan HD High-resolution analysis of CNVs constitutional postnatal samples
Analysis of gains and loss for constitutional postnatal samples
Detection of gross aneuploidies at low cost and low resolution
Probe Details
High Density coverage with > 2.6 million probes
CNV Probes = 550,000
SNP Probes = 200,000
Total Probes = 750,000
CNV Probes = 18,018
SNP Probes = 148,450
Total Probes = 315,000
Sample Types
Blood, Buccal Swabs, Saliva, fresh & frozen tissues, uncultured or cultured cells, CVS , Amniocentesis,POC, etc.
Blood, Buccal Swabs, Saliva, fresh & frozen tissues, uncultured or cultured cells, CVS, Amniocentesis, POC, etc.
Blood, Buccal Swabs, Saliva, fresh & frozen tissues, uncultured or cultured cells, CVS , Amniocentesis,POC, etc
Analytical Claims
Gains < 10-25 Kb
Losses < 10-25 kb
AOH> 1mb
Mocaissim > ~ 15%
Gains 200-400 kb
Losses 200-400 kb
AOH> 5 mb
Mocaissim > ~ 15-20%
Gains 2 mb
Losses 1 mb
AOH> ~5 mb
Mocaissim > ~ 20%
396 genes at 25m/100kb

Chromosomal Microarray Advantage

Chromsomal Microarray
  • Low Diagnostic Yield Only 3% of cases have a diagnosis made
  • High TAT Sample to Result – 7-14 days
  • Requires live cells - Prone to culture failure
  • Small changes low detection limit 5MB is the smallest deletion you can detect with a microscope and a human eye
  • Very specially trained people Difficult to scale
  • Subjective method Prone to human error
  • Can only identify known aberrations Requires prior knowledge or a suspected diagnosis to enable probe selection Cannot be used to discover new ones
  • Low Diagnostic Yield Only 3% of cases have a diagnosis made
  • Miss small changes low detection limit Resolution 80Kb-1Mb prove to culture future
  • Diagnostic yield ~30% More information per test/ fewer retests/reflex tests. Greater number of patients benefit from definitive diagnosis
  • Quicker time to result 3 days versus 7 -14 days Rapid turn round of samples
  • Superior resolution Whole genome / high density CN and SNP content Increased confidence in results
  • Quantitative vs subjective Increased confidence


ACOG 2016

Most genetic changes identified by chromosomal microarray analysis that typically are not identified on standard karyotype are not associated with increasing maternal age: therefore, the use of this test can be considered for all women who undergo prenatal diagnostic testing, regardless of age. Prenatal chromosomal microarray analysis is recommended for a patient with a fetus with one or more major structural abnormalities identified on ultrasonographic examination and who is undergoing invasive prenatal diagnosis. This test typically can replace the need for fetel karyotype.

Society of Maternal & Fetal Medicine 2016

The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) recommend that all pregnant women should be offered prenatal assessment for aneuploidy by screening or diagnostic testing regardless of maternal age or other risk factors. The differences between screening and diagnostic testing also should be discussed. SMFM recommends that CMA be offered when genetic analysis is performed in cases with fetal Structural anomalies and /or stillbirth and replaces the need for fetal karyotype in these cases.

For any further information, please fill in the form below and we will call you back shortly:

Frequently asked questions

Find answers to your lab service questions in our FAQ section

A microarray is a powerful tool used to analyze the expression of thousands of genes simultaneously. It consists of a grid of microscopic spots, each containing DNA or RNA probes. These probes can hybridize with target molecules, allowing the simultaneous analysis of gene expression or genetic variation.

Microarray analysis enables researchers to study gene expression patterns, identify genetic variations, and understand molecular mechanisms underlying diseases. It is invaluable for drug discovery, biomarker identification, and personalized medicine.

To initiate a microarray project, you can contact our customer support team through the contact information provided on our website. We will guide you through the process, including project consultation, sample submission, and project timeline.

Yes, our team of experts can collaborate with you to design your experiment, select the appropriate microarray platform, and provide comprehensive data analysis services. We strive to ensure that your research goals are met effectively.

Orbito Asia provides comprehensive microarray services, including gene expression profiling, SNP genotyping, and comparative genomic hybridization (CGH). Our services cater to diverse research needs in genomics and molecular biology.

Orbito Asia offers a range of microarrays, including DNA microarrays for genotyping and CGH, as well as RNA microarrays for gene expression profiling. We also provide custom microarray solutions to meet specific research requirements.

Absolutely. Our technical support team is available to assist you throughout the duration of your project and beyond. We are committed to ensuring that your experience with Orbito Asia is seamless and successful.

Turnaround time can vary depending on the specific scope and requirements of your project. Our team will provide you with a detailed timeline during the project initiation phase, taking into consideration factors such as sample size and complexity.